Shots:

• The two companies expand their 2018 agreement to develop and manufacture five candidates from ImmuneOncia's pipeline. The partners expand the collaboration to bring new treatments such as IMC-002 for cancer patients
• Samsung Biologics to provide CDO services from cell line development- process development- non-clinical/clinical material manufacturing- to IND submission supporting the global clinical trials of five candidates
• ImmuneOncia's portfolio consists of immune checkpoint Abs including IMC-002- a CD47-targeting Ab- currently evaluating in global P-I study based on IND approval obtained through the development and manufacturing partnership with Samsung Biologics

Click here to read full press release/ article | Ref: PRNewswire | Image: LinkedIn